Opening minds & creating new possibilities


Advanced Therapeutics Inspired By Psychedelics

Who We Are

NeoLumina is a life sciences company that aims to develop effective first-line therapeutics based on psychedelics for mental health disorders such as eating disorders, depression, anxiety, pain, and addictions.

We are developing novel approaches that have the potential to be more efficacious, accessible and physiologically sustainable in order to treat the large and growing problem related to mental health.

Our Strategy

Natural molecule products

Proprietary drug candidates based on psilocybin and psilocin. 
Lead product candidate being prepared for clinical trials.

Creation of unique new molecules

New chemical entity (NCE) drug discovery and development.
Unique molecules created.

Mental Illness by the Numbers

Affects 1 in every 8 people

Approximately 1 billion people in the world live with a mental disorder (World Health Organization)

703,000 suicides a year

An estimated 703,000 people a year take their life around the world. For every suicide, there are likely 20 other people making a suicide attempt and many more have serious thoughts of suicide (World Health Organization)

Mental disorders on the rise

Mental disorders are on the rise in every country in the world and projected to cost the global economy $16 trillion by 2030 (Lancet Commission Report)

Value Proposition

The foundation is formed by the active natural psychedelic molecules, psilocybin and psilocin, which are the basis for the value proposition, with one proprietary
psilocybin-based product candidate being prepared for human studies.

General Inquiries

Investor Relations